Announcement
USC scientists engineer renewable immune cells for scalable cancer immunotherapy
Researchers published a Cell study showing that engineered granulocyte-monocyte progenitors (GMPs) can self-renew extensively in the lab, be genetically modified with CAR receptors, and continuously produce cancer-fighting cells like macrophages in mouse models, slowing blood and solid tumors.
TLDR
The breakthrough addresses major challenges in CAR-T and macrophage therapies: limited supply, manufacturing costs, and cell persistence. An 'off-the-shelf' renewable source could enable more accessible and scalable immunotherapies beyond cancer, potentially transforming how immune-cell treatments are produced and deployed.
Combined views
721
1 Source, first seen ago